Clene Announces $10 Million Debt Facility for CNM-Au8 Treatment Development
Clene Inc. (NASDAQ: CLNN) secures $10 million debt facility to support the development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, addressing FDA data requirements for regulatory approval.
This news matters as it highlights Clene's strategic financial move to secure funding for the development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, potentially impacting the future of neurological disease treatment.